ABS-1230 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01 (month) in 3mo
ESTIMATED |
READOUT
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical
Phase 2 · KCNT1-Related Epilepsy |
Actio Biosciences, Inc. | ABS-1230 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|